Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4+ T cell recovery after the initiation of antiretroviral therapy for HIV disease

Table 1 Clinical descriptions for cross-sectional HIV patients

Patients	N	VL (copies/mL)^#	CD4 (cells/ul)^#	Mean age^#	Male%
HIV Viral Controllers^a	31	75 (75–184.3)	710 (514–945.5)	45.5 (43–52.7)	64.5%
HIV Viremic^b	34	89246 (45295.5–174381)	304 (202.2–451)	43 (39.2–47.7)	79.4%
ART-suppressed^c	34	75 (50–75)	388.5 (313.5–500.2)	47 (41.7–50)	79.4%
Seronegative	30	NA	NA	42 (37.2–45.7)	100.0%

^aHIV viral controllers were defined as untreated subjects with at least three plasma HIV VL < 1,000 copies/mL during a 12 month period.
^bHIV viremics were defined as untreated individuals with VL > 10,000 copies/ml.
^cART-suppressed subjects had VL < 75 copies/mL for a period between 2–4 years after treatment initiation, with only one viral blip >1000 copies/mL permissible during the analysis time.
^#Values are expressed as median ± interquartile range.

ISSN: 1742-6405